Story thread · 2 reports / 2 sources
Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
endpts.com · 6h · first report
Investors are pumping $123 million into a tiny Michigan biotech that is resurrecting an Astellas cancer drug for an eye disease that has attracted lots of VC and pharma attention in recent years. Sling Therapeutics ...
The coverage
- Sling banks $123M for an experimental thyroid eye disease pill
biopharmadive.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.